All In Biotech

Free tool

Medicare drug spending

CMS's Spending by Drug data: what Medicare paid for each drug before manufacturer rebates. Part D covers drugs dispensed by pharmacies; Part B covers drugs given in a doctor's office or hospital outpatient department. Commercial and list prices are not public data and are not shown.

Last checked: Nov 20, 2026Latest source record: 2024 calendar yearSource: CMS (Medicare Part D Spending by Drug : 2024-01-01; Medicare Part B Spending by Drug : 2024-01-01)Methods & limitations

Part D, 2024

$288.7B

Gross drug spending in the dataset

Part B, 2024

$60.8B

Gross drug spending in the dataset

Drugs listed

4

Part D and Part B

Total spending by year

  • Part D
  • Part B
View as table
YearPart DPart B
2020$194,092,038,339$37,778,829,680
2021$213,513,349,361$40,135,340,775
2022$239,779,215,689$44,241,259,745
2023$275,808,918,753$50,775,853,083
2024$288,667,842,058$60,838,164,403
Reset

Top 4 by total spending

2024 figures. Growth compares with 2023. Per-beneficiary ranks skip drugs with fewer than 11 beneficiaries.

DrugPartSpendingChangeBeneficiariesPer beneficiaryPer unit
Yuflyma(Cf) Autoinject (2 Pck)

Adalimumab-Aaty

D$22.4M+19506%451$49,557$6,429.81
Yuflyma(Cf) Autoinjector

Adalimumab-Aaty

D$5.8Mn/a172$33,737$3,487.77
Yuflyma(Cf) (2 Pack)

Adalimumab-Aaty

D$2.7Mn/a56$49,047$6,128.13
Yuflyma(Cf) Ai Crohn'S-Uc-Hs

Adalimumab-Aaty

D$136Kn/a13$10,424$3,474.51

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.